The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 51, 2013, Pages

  Josefsson, Lina ^a,b   Von Stockenstrom, Susanne ^a,b   Faria, Nuno R ^c   Sinclair, Elizabeth ^d   Bacchetti, Peter ^d   Killian, Maudi ^d   Epling, Lorrie ^d   Tan, Alice ^d   Ho, Terence ^d   Lemey, Philippe ^c   Shao, Wei ^e   Hunt, Peter W ^d   Somsouk, Ma ^d   Wylie, Will ^f   Douek, Daniel C ^f   Loeb, Lisa ^d   Custer, Jeff ^d   Hoh, Rebecca ^d   Poole, Lauren ^d   Deeks, Steven G ^d   Hecht, Frederick ^d   Palmer, Sarah ^a,b,g,h   more..

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SAIC FREDERICK INC   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g WESTMEAD HOSPITAL   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CD45RO ANTIGEN; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA;

ARTICLE; BONE MARROW CELL; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL DIVISION; CELL PROLIFERATION; CLINICAL ARTICLE; DISEASE DURATION; DNA SEQUENCE; GENETIC ALGORITHM; GENETIC SIMILARITY; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; INTESTINE LYMPHATIC TISSUE; LONG TERM CARE; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; PHYLOGENETIC TREE; PHYLOGENY; PRIORITY JOURNAL; RNA SEQUENCE; T LYMPHOCYTE SUBPOPULATION; VIRUS CARRIER; VIRUS LOAD; VIRUS REPLICATION;

EID: 84890847660     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1308313110     Document Type: Article

References (57)

1. Deeks SG, et al.; International AIDS Society Scientific Working Group on HIV Cure (2012) Towards an HIV cure: A global scientific strategy. Nat Rev Immunol 12(8): 607-614.
2. Dornadula G, et al. (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282(17):1627-1632.
3. Havlir DV, et al.; Gilead 903 Study Team (2005) Predictors of residual viremia in HIVinfected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 191(7):1164-1168.
4. Maldarelli F, et al. (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3(4):e46.
5. Zhang L, et al. (1999) Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340(21):1605-1613.
6. Lewin SR, et al. (1999) Use of real-Time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-Infected individuals on prolonged effective antiretroviral therapy. J Virol 73(7):6099-6103.
7. Palmer S, et al. (2008) Low-Level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105(10):3879-3884.
8. Chun TW, et al. (1998) Early establishment of a pool of latently infected, resting CD4 (+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 95(15):8869-8873.
9. Finzi D, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278(5341):1295-1300.
10. Wong JK, et al. (1997) Recovery of replication-Competent HIV despite prolonged suppression of plasma viremia. Science 278(5341):1291-1295.
11. Burke B, et al. (2007) Primary cell model for activation-Inducible human immunodeficiency virus. J Virol 81(14):7424-7434.
12. Saleh S, et al. (2007) CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: A novel model of HIV-1 latency. Blood 110(13):4161-4164.
13. Swiggard WJ, et al. (2005) Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol 79(22): 14179-14188.
14. Chomont N, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15(8):893-900.
15. Wightman F, et al. (2010) Both CD31(+) and CD31 naive CD4(+) T cells are persistent HIV type 1-Infected reservoirs in individuals receiving antiretroviral therapy. J Infect Dis 202(11):1738-1748.
16. Palmer S, Josefsson L, Coffin JM (2011) HIV reservoirs and the possibility of a cure for HIV infection. J Intern Med 270(6):550-560.
17. Chun TW, et al. (2008) Persistence of HIV in gut-Associated lymphoid tissue despite long-Term antiretroviral therapy. J Infect Dis 197(5):714-720.
18. Yukl SA, et al. (2010) Differences in HIV burden and immune activation within the gut of HIV-Positive patients receiving suppressive antiretroviral therapy. J Infect Dis 202(10):1553-1561.
19. Anton PA, et al. (2003) Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 17(1):53-63.
20. Di Stefano M, et al. (2001) Intracellular and cell-Free (infectious) HIV-1 in rectal mucosa. J Med Virol 65(4):637-643.
21. Lampinen TM, et al. (2000) Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 14(5):F69-F75.
22. Poles MA, et al. (2006) Lack of decay of HIV-1 in gut-Associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 43(1):65-68.
23. Evering TH, et al. (2012) Absence of HIV-1 evolution in the gut-Associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 8(2):e1002506.
24. Kieffer TL, et al. (2004) Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 189(8):1452-1465.
25. Mens H, et al. (2007) Investigating signs of recent evolution in the pool of proviral HIV type 1 DNA during years of successful HAART. AIDS Res Hum Retroviruses 23(1): 107-115.
26. Persaud D, et al. (2007) Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 23(3):381-390.
27. Bailey JR, et al. (2006) Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 80(13):6441-6457.
28. Nottet HS, et al. (2009) HIV-1 can persist in aged memory CD4+ T lymphocytes with minimal signs of evolution after 8.3 years of effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 50(4):345-353.
29. Kim H, Perelson AS (2006) Viral and latent reservoir persistence in HIV-1-Infected patients on therapy. PLOS Comput Biol 2(10):e135.
30. Dinoso JB, et al. (2009) Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 106(23):9403-9408.
31. McMahon D, et al. (2010) Short-Course raltegravir intensification does not reduce persistent low-Level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 50(6):912-919.
32. Buzón MJ, et al. (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-Suppressed subjects. Nat Med 16(4):460-465.
33. Yukl SA, et al. (2010) Effect of raltegravir-Containing intensification on HIV burden and T-Cell activation in multiple gut sites of HIV-Positive adults on suppressive antiretroviral therapy. AIDS 24(16):2451-2460.
34. Mexas AM, et al. (2012) Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS 26(18):2295-2306.
35. Zhu T, et al. (2002) Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 76(2):707-716.
36. Lambotte O, et al. (2000) Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 23(2):114-119.
37. Zalar A, et al. (2010) Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART. Antiviral Res 87(2):269-271.
38. Zárate S, Pond SL, Shapshak P, Frost SD (2007) Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus typee. J Virol 81(12):6643-6651.
39. Drummond AJ, Suchard MA, Xie D, Rambaut A (2012) Bayesian phylogenetics with BEAUti and the BEAST 1.7. Mol Biol Evol 29(8):1969-1973.
40. Lemey P, Rambaut A, Pybus OG (2006) HIV evolutionary dynamics within and among hosts. AIDS Rev 8(3):125-140.
41. Michie CA, McLean A, Alcock C, Beverley PC (1992) Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360(6401):264-265.
42. Strain MC, et al. (2005) Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 191(9):1410-1418.
43. Almodóvar S, et al. (2007) HIV-1 infection of monocytes is directly related to the success of HAART. Virology 369(1):35-46.
44. Ellery PJ, et al. (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 178(10):6581-6589.
45. Fulcher JA, et al. (2004) Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J Virol 78(15): 7883-7893.
46. Eriksson S, et al. (2013) Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9(2):e1003174.
47. Josefsson L, et al. (2012) Hematopoietic precursor cells isolated from patients on longterm suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis 206(1):28-34.
48. Palmer S, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-Experienced patients are missed by standard genotype analysis. J Clin Microbiol 43(1):406-413.
49. Kearney M, et al. (2009) Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 83(6):2715-2727.
50. Kearney M, et al. (2008) Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 22(4):497-501.
51. Kosakovsky Pond SL, Posada D, Gravenor MB, Woelk CH, Frost SDW (2006) GARD: A genetic algorithm for recombination detection. Bioinformatics 22(24):3096-3098.
52. Guindon S, et al. (2010) New algorithms and methods to estimate maximum-Likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst Biol 59(3):307-321.
53. Gouy M, Guindon S, Gascuel O (2010) SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol 27(2):221-224.
54. Wang TH, Donaldson YK, Brettle RP, Bell JE, Simmonds P (2001) Identification of shared populations of human immunodeficiency virus type 1 infecting microglia and tissue macrophages outside the central nervous system. J Virol 75(23):11686-11699.
55. Hudson RR, Slatkin M, Maddison WP (1992) Estimation of levels of gene flow from DNA sequence data. Genetics 132(2):583-589.
56. Pond SL, Frost SD, Muse SV (2005) HyPhy: Hypothesis testing using phylogenies. Bioinformatics 21(5):676-679.
57. Minin VN, Bloomquist EW, Suchard MA (2008) Smooth skyride through a rough skyline: Bayesian coalescent-Based inference of population dynamics. Mol Biol Evol 25(7):1459-1471.